Anti-Mouse IFNß [Clone MIB-5E9.1] — Purified in vivo GOLD™ Functional Grade

Clone MIB-5E9.1 is an Armenian hamster monoclonal antibody widely used in vivo in mice to neutralize interferon-beta (IFN-β), primarily to study the role and mechanisms of type I interferon signaling in various disease and immunological models.

Key in vivo applications include:

• Neutralization of mouse IFN-β bioactivity: MIB-5E9.1 is administered to mice to block endogenous IFN-β, allowing researchers to dissect the biological functions of IFN-β during infection, tumor growth, or immune responses.
• Mechanistic studies in infectious disease and cancer: By neutralizing IFN-β, the antibody helps elucidate the role of interferon-beta in host defense, antitumor immunity, and inflammatory processes.
• Autoimmune disease models: Used in mouse models such as experimental autoimmune encephalomyelitis (EAE, a model for multiple sclerosis), neutralization of IFN-β clarifies its regulatory or pathogenic contributions in CNS inflammation.
• Immunological challenge experiments: MIB-5E9.1 allows manipulation of the IFN-β axis in vivo during immunization, tolerance induction, or cytokine response assays in mice.

Supporting details:

• Clone MIB-5E9.1 is specifically recommended for in vivo functional blocking/neutralization studies, and is validated for use in such experiments by multiple suppliers and research protocols.
• It is also used in related applications such as western blot and ELISA, but the in vivo application is specifically the neutralization (functional blockade) of mouse IFN-β.
• The typical aim is to unravel the roles of type I interferon in immune modulation, inflammation, antiviral responses, and tumor surveillance by comparing treated and control mice.

In summary, the most common in vivo application of MIB-5E9.1 in mice is the neutralization of mouse IFN-β to investigate its function in models of infection, cancer, and autoimmunity.

In the literature, the MIB-5E9.1 antibody, which targets mouse IFN-β, is often used alongside other cytokine and checkpoint antibodies. These include:

• IFNα Antibodies: Such as the TIF-3C5 clone, which is used for studying type I interferons and their role in immune responses.

• IFNγ Antibodies: Like the XMG1.2 and H22 clones, which are commonly used to study IFN-γ-dependent immune processes.

• IFNAR-1 Antibodies: Clones such as MAR1-5A3 target the interferon receptor, allowing researchers to study the effects of type I interferon signaling.

• Checkpoint Antibodies: These include antibodies against proteins involved in immune checkpoint regulation, such as PD-1/PD-L1 and CTLA-4, which are crucial for understanding immune modulation mechanisms.

These antibodies are used in various applications, including neutralization assays, Western blotting, ELISA, and in vivo studies, to investigate immune responses and cytokine dynamics.

There are no key scientific findings directly linked to the use of clone MIB-5E9.1 in the cited literature; instead, references focus primarily on the technical specifications, recommended uses, and detection capabilities of this antibody for mouse interferon beta (IFNβ).

Key points from available sources:

• Clone MIB-5E9.1 is an Armenian Hamster anti-mouse IFNβ monoclonal antibody, commonly used for detection and neutralization of mouse IFNβ in various research contexts, including ELISA and in vivo or in vitro functional studies.
• The literature and product data sheets describe its specificity for mouse IFNβ, its purification methodology (affinity chromatography), and its utility in sandwich ELISA as a detection antibody, as well as for functional assays requiring neutralization or detection of type I interferon responses in mice.
• There are no notable discoveries or unique research findings specifically attributed to experiments using clone MIB-5E9.1 according to the cited literature, i.e., it has not been a focus of primary publications reporting novel mechanistic or clinical breakthroughs.

In summary, clone MIB-5E9.1 is well-characterized as a research tool for mouse IFNβ studies, with its principal citation value lying in its technical application rather than in yielding unique scientific findings or biological insights.

The dosing regimens for the clone MIB-5E9.1, an Armenian hamster anti-mouse IFN-β monoclonal antibody, can vary depending on the specific mouse model and the experimental objectives. However, detailed specific dosing regimens for different mouse models are not explicitly outlined in the available search results. Here are some general considerations for dosing antibodies in mouse models:

1. General Dosing for Mouse Models: Antibodies like MIB-5E9.1 are often administered via intraperitoneal injection. For many antibodies, standard dosing ranges from 100 to 500 μg per mouse, depending on the target and application.

2. Optimal Concentrations in Specific Studies: For quantification of mouse IFN-β, this antibody has been used at concentrations of 2 μg/mL in certain studies. However, optimal dosing in vivo can vary based on the specific experimental setup and desired effect.

3. Neutralization Experiments: Since MIB-5E9.1 is used for neutralizing mouse IFN-β bioactivity, researchers typically determine their own optimal working dilution for specific applications.

In summary, while specific dosing regimens for MIB-5E9.1 across different mouse models are not detailed in the search results, researchers generally optimize dosing based on the experimental goals and models used. It is important to consult peer-reviewed literature or specific product datasheets for guidance on using this antibody in experimental settings.